A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.

Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. This latest CF drug adds even more firepower to a franchise ...

1 Day VRTX -0.71% DJIA 0.38% S&P 500 0.53% Health Care/Life Sciences 0.19% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...